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the European Academy of Pediatrics (EAP) officially accepted PA as a certified and acknowledged subspeciality in 1999. 
| STATUS QUO IN PEDIATRIC ALLERGOLOGY IN EUROPE
More than two decades after the EAP officially accepted PA as a certified and acknowledged subspecialty within pediatrics, there are still striking differences across Europe in the training pathways for doctors seeing children with allergic disease(s). The types of doctors currently engaged in PA in Europe can be outlined as followed:
1. Those fully trained in general pediatrics with (extra) dedicated time in allergy. These are pediatricians who have a special interest in allergy, and the allergy-dedicated training duration varies among countries, for example, in UK where this is known as SPIN (special interest) in allergy and tends to be for those who wish to work in secondary service with dedicated allergy clinics.
2.
Those trained where PA is a subspecialty within pediatrics, namely through an (integrated) general pediatrics (core) training and full specialist allergy training program leading to accreditation as pediatric allergists. In these countries, PA is regarded as a full (sub)specialty, for example, Sweden, Turkey, Denmark, and UK. Subspecialty pediatric allergy training in the UK is a 3-year program approved by the Royal College of Paediatrics and Child Health, and subspecialty accreditation is awarded by the General Medical Council; this is the usual route to working in a tertiary or academic UK allergy unit. In Turkey, after 5 years of general pediatric specialty, the pediatric immunology and allergy training are independent 3-year full specialty program. Of note, in some countries, pediatricians that have been dedicated to seeing allergic children for a specified sufficient period of time have been granted accreditation as pediatric allergists (such as in Spain with pediatricians consulting allergic children for 5 years or more).
3.
Those who have completed core training in adult general medicine and, in some cases, a short or equal period of pediatrics, followed by a combined clinical training in child and adult allergy. These are allergists and allergy is considered as a full (sub)specialty.
Representative examples of countries implementing this training system are Greece, Portugal, Spain, France, and Romania.
4.
A fourth setting exists where allergy is not regarded as specialty, and the onus is on the individual physician to train themselves to feel confident in seeing children with allergic problems. This may happen in the case of adult ENT and ophthalmology surgery specialists in Germany, for example, and the Workshop agreed this situation is suboptimal for both the patients and the physicians involved. This setting includes many clinicians appointed to posts in the 1990s and 2000s.
It is also vital to acknowledge and consider the experienced nonmedical healthcare professionals (HCP) who support and add value to the optimal diagnosis and management of allergy in children. Countries differ in the training and utilization of allied HCP within the allergy teams.
Specialist nursing and dietetic clinics already occur in some allergy centers in the UK and Scandinavia. 2 However, to date, the authors are unaware of an accredited curriculum and certification in allergy in Allied Health, although ratified 2-year training programs for asthma or eczema exist. This issue could and should be addressed with the appropriate stakeholders. Research training is considered an essential aspect of the PA curriculum. Furthermore, attendance at International Congresses and giving 2 to 3 presentations in such meetings are highly recommended.
| PEDIATRIC ALLERGY EXAMS
A knowledge-based assessment is desirable and preferably included 
| NETWORKS FOR PEDIATRIC ALLERGISTS ACROSS EUROPE
In order to meet the needs of children and families with allergic disease(s), the pediatric allergist is highly encouraged to develop sev- 
| Multidisciplinary team pediatric allergy clinics
Pediatric subspecialty services are becoming increasingly multidis- 
| Primary care
In many European countries, the majority of patients with allergic disease(s) will consult first with their primary caregiver (eg, general 
| Regional networks
In some European countries, regional networks are increasingly popular, as they facilitate education and information dissemination among pediatric allergy MDT across the region. Tertiary centers tend to coordinate meetings, with attendance from MDT members from secondary care hospitals and occasionally by primary care. There is an opportunity to collect regional data, for example, for asthma, food challenges, and creating regional guidelines, such as standardized food challenge, referral pathways for drug allergy, or even to conduct audits. Most importantly, there is an opportunity to discuss cases, be it simple or complex, among experts from the tertiary center. We strongly support the constitution of regional clinical networks led by trained and experienced pediatric allergists, and including physicians and allied health professionals involved in the care of allergic children and adolescents. Clinical and research networks also need to focus on strategic partnerships and collaboration with adult colleagues to better understand how to support each other's needs and to align activities.
| International networking
Well-established PA centers can offer great support to centers in other countries where PA is emerging. Short, as well as longer term, visits to both sides of the network should be encouraged, not only for trainees, but also for established professionals. Moving to a country with a higher cost of living is a major problem impairing the ability to take up Certification of PA centers for training through ETC-PA should be encouraged. Certified centers will be identified as resource centers for exchange and will testify to a high level of clinical care. In addition, it is important to acknowledge centers that provide excellent clinical or research exposure to specific aspects of PA, to avoid oversubscription of well-known centers, and to engage and develop new centers of excellence.
| Medical students and pediatric trainees
Provision of allergy teaching within the undergraduate curriculum is variable throughout Europe. Medical schools might allocate a most commonly restricted time for undergraduate allergy teaching. It is vital that undergraduate medical students are exposed to the specialty to foster the interest and enthusiasm of individuals interest and enthusiasm in individuals who may become future specialists in the field.
Similarly, allergy training should be offered to pediatric trainees in order to generate interest and recruitment into PA.
| Social media and modern communication Apps
Digital tools are useful for communication among healthcare professionals who provide pediatric allergy services. In Turkey, for instance, a closed WhatsApp group was created to facilitate case discussions among HCP who deal with children with allergic disease(s).
Facebook is a popular platform for patients/families to interact.
Similarly, Twitter has been gaining increasing interest the last years in the medical community as its users can:
follow a Journal's latest articles (eg, through the hashtag #PAI_
Journal for all PAI papers) or many of the key messages presented in Meetings' sessions (eg, via #EAACI2017 for all twitter posts on the EAACI Congress 2017),
participate in Twitter discussions meant either for professionals (eg, via #AboutAllergy for twitter discussions organized by EAACI)
or patients and lay public (eg, through #AllergyReady).
These potentially powerful learning and communication tools also require some guidance for optimal clinical conduct and governance and need to be identifiably distinct and separate from ungoverned patient/parent sites which are not backed by science and medical expertise. For all information in the public domain, strict patient confidentiality has to be adhered to, in accordance with, local trust guidelines. EAACI has an annex dedicated to the proper use of social media by HCP as part of the EAACI code of ethics. 4 In time,
there is likely to be a need for formal education on this included as part of training.
| Media
Pediatric allergology is a topic of wide interest to the media. Aside from social media, some may find it useful to engage with the traditional media of communication in order to ensure seamless dissemination of the correct information. Effective and coordinated communication can avoid negative publicity due to fatalities, near-misses from food anaphylaxis, for example, or may be better presented as a result.
Additionally, effective liaison with and through the media should be communicated at national and EU level aiming at promoting the prioritization of allergic diseases.
| Patient organizations
Pediatric allergists engage with and support professional patient organizations to further support families. This creates an educational opportunity-ensuring that scientific information is understood by patients and families for better outcomes and that our patients' needs are met and their priorities held paramount.
| Pharmacists
In addition to their knowledge of medicines, pharmacists also provide advice, information, and treatment for a number of chronic conditions and play a vital part in health promotion and disease prevention initiatives. Pharmacists are educated to support patients manage medicines and their side effects effectively 5 while they contribute to improved patient adherence. Therefore, they are important liaisons for pediatric allergists and can further contribute to increased awareness of allergic diseases.
| CURRENT STATE AND FUTURE OF PEDIATRIC ALLERGY RESEARCH IN EUROPE
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| Prevention of allergic disease(s)
Research is ongoing for the prevention of eczema, food or respiratory allergy, or required in the epidemiology of allergy; genetics, immunology, molecular, and cellular mechanisms of the allergic immune response and for drugs suitable for children.
Basic science research is underrepresented in pediatric medicine, and this should be strategically highlighted to the EU and national funding agencies. Recent studies have made significant inroads into understanding the pathophysiology of tolerance induction, as well as the specifics of primary food allergy prevention. These messages necessarily lead to further epidemiologic and clinical translational and intervention studies. Pediatric medicine is a fertile research ground for cohort studies but, for reasons not fully explored in the remit of this paper, it has been historically weak on trials and this is due to change.
| Diagnostic tools and management in PA
Better child and young person-centric diagnostic tools are needed to avoid misdiagnosis or unnecessary positive challenges. In vitro diagnostics appear promising with respect to predicting positive food or drug challenges, but there is much work to be done in relation to easier and accurate diagnosis of non-IgE allergy. Research in diagnostic biomarkers also needs to take into account if, and how, the potentially different physiology of children is important at different age ranges.
Accurate and earlier diagnostics for allergic diseases and risk of development would help prevent missing the window of opportunity and thus optimize chances of primary and secondary prevention.
At the same time, effective research in drug allergy in childrenand more effective means of navigating difficult and slow processes related to drug research in children-is much needed. An example of important public health intervention resulting from such research is the removal of pholcodine from over the counter products, such as children cough syrups. The wide-scale reduction in exposure to this allergen means potentially fatal anaphylactic reactions to neuromuscular blocking drugs may be prevented.
Allergen-specific immunotherapy (AIT), first described in 1908, has recently been rejuvenated with respect to oral, epicutaneous, sublingual, or subcutaneous modalities for food allergy as well as with the introduction of peptides instead of whole extracts against allergic rhinitis. 6 More child-friendly and better access to AIT is required, as is better standardization and training. Ongoing surveillance of adverse side effects and tolerability as regards quality of life is imperative.
| New drug development and trials for pediatric safety and efficacy
It is known that drugs for neonates, infants, and very young children need to be reviewed with respect to drug absorption, distribution, metabolism, and excretion and the implication on drug usage, especially dose. However, for older children, despite acknowledgment that brain maturation may take up to 25 years, pharmacological or metabolic characteristics may be as for adults. Of note though, EU pediatric regulation requires a pediatric investigation plan (PIP) for every new drug as a condition for marketing approval.
It is important to discuss that AIT products in the EU were exposed to two key legislations in 2007/2008: a requirement for PIP submission, and the German therapy allergen ordinance. 7 The latter made it mandatory for manufacturers to register every AIT product, despite being in use for decades. As Germany is the largest market for AIT products, this affected all allergen AIT manufacturers in Europe. More than a hundred PIPs were submitted in short time, resulting finally in a massive study program proposed to involve 58 five-year double-blind randomized placebo-controlled allergen AIT safety and efficacy trials with several hundred participants. The deadline for these studies is December 2031. While aspects of current AIT products on the market need appropriate study and review, there is concern that the requirement for participation of thousands of children and adolescents potentially leaves children at risk of unnecessary morbidity and, those assigned to placebo groups, at risk of progression or march of allergic disease.
Many clinical specialists are unaware of this issue and would rationally question the necessity of trials which would hold up the ability of children to benefit from medications that have been proven to be of benefit in adults. The PIP system is due for discussion in the EU parliament, and it is hoped that representatives from PA and EAACI will raise their voice together with those from other pediatric specialties 8 to review the EMA's position which risks suffocating pharmaceutic innovation.
| Innovation and technology
Innovation and technology for better personalized clinical care, public health, and research tools is a growing and rapidly changing field. EAACI is already cognisant of this fact and a mobile health taskforce has been created to evaluate and develop the organization's approach. The promise is of more effective tools to monitor patients, to educate patients or professionals, and to improve adherence. These potential benefits need to be rigorously evaluated to assess the true impact and whether or not the mobile health or digital tools are indeed effective in improving education, adherence, and self-efficacy in the management of allergic diseases.
Collaboration and engagement with primary care and public health as well as extra pediatric groups, such as health economists and T A B L E 1 Key areas for investment in pediatric allergy research
• Prevention of allergic disease(s)
• Better diagnostic tools and evidence-based management • New drug development and trials, more streamlined, ethical, and relevant processes and regulation • Innovation and technology for better personalized clinical care, public health, and research tools. Improved strategic communication and collaboration with public health, economists, and regulatory bodies and the public and press • Fostering networks for research appropriately skilled tech expertise, will be required to inform assessment and trials.
| Improved strategic communication and collaboration
Improved strategic communication and collaboration is related to public health, economists, regulatory bodies, the lay public, and the press. Pediatric allergists must be strong advocates for their patients.
| Fostering networks for research
The need for the development of pan-European registries to facilitate research and care was highlighted in an EAACI statement by Professor Papadopoulos et al. in 2012. 9 As an example of the valuable information a registry can carry, the European Anaphylaxis Registry has recently provided significant epidemiologic information on the eliciting factors of anaphylaxis in children and adolescents. 
| PLANNING AHEAD
A strategic plan to enhance PA as a specialty should focus on its unique strengths and aim to minimize its weaknesses. A focus on pediatrics and on primary, secondary, and tertiary prevention also favors health promotion and cost-effectiveness of EU health systems. PA requires a defined expertise, while immense research and increased interest are taking place in this field. PA, as a pediatric subspecialty, has the gratifying ability to intervene early and to improve health and quality of life of allergic children, adolescents, and their families, over the long term. Nonetheless, pediatric allergology is currently not recognized in all countries, and there is a lack of visibility and awareness of the benefits of implementing this subspecialty. The wide diversity between nations and the differential approach of health implementation priorities will continue to be a basis of weaknesses for PA.
Opportunities are emerging from the rising number of allergic children, and PA has the possibility to modulate disease progression and, potentially, to provide primary prevention. Allergy at all ages is still under-recognized as a health issue by other specialties, as well as by government bodies, and this has adverse implications for health and research budgets.
Journals publishing on pediatric allergy should inspire and demand quality and timely research by ensuring high acceptance standards, critical expert reviews, rapid turnaround times, and electronic publication. 
| CONCLUSION
Pediatric allergology as a subspecialty is being better recognized, and a universally acceptable standard for training and accreditation is being refined. Original research should be promoted, as well as outstanding review articles for key topics. The rapid publication of meeting reports, with the aim to provide both an overview and a discussion of the latest advances presented in pediatric research would be welcomed.
The role for EAACI and similar organizations worldwide who wish to prioritize the agenda for PA needs to include the following:
broadening of national representation, lobbying for recognition across stakeholder countries, the free movement of realistically funded specialists in training, and accurate and well-communicated reports on the economic benefits of disease control and prevention for commissioners, policy, and funding bodies. These efforts ultimately have one aim-to improve the health and quality of life of children predisposed to and suffering with allergic disease.
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